Patents by Inventor M. Menon

M. Menon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING HCV
    Publication number: 20140274934
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Barry M. Bernstein, Sandeep Dutta, Wei Liu, Thomas J. Podsadecki, Andrew L. Campbell, Rajeev M. Menon, Chih-Wei Lin, Tianli Wang, Walid M. Awni
  • METHODS FOR TREATING HCV
    Publication number: 20140275099
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Barry M. Bernstein, Sandeep Dutta, Wei Liu, Thomas J. Podsadecki, Andrew L. Campbell, Rajeev M. Menon, Chih-Wei Lin, Tianli Wang, Walid M. Awni
  • Methods for treating HCV
    Patent number: 8809265
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: August 19, 2014
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Animal meal that includes fungal biomass
    Patent number: 8728550
    Abstract: Disclosed herein are compositions comprising an isolated cellulose degrading fungus. Also disclosed are culture compositions and bioreactor compositions comprising the cellulose degrading fungus. Further described herein are filtration and extraction devices comprising the cellulose degrading fungus. Still further disclosed are bioprocessing facilities for and methods for producing co-products resulting from one or more bioprocesses of the cellulose degrading fungus.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: May 20, 2014
    Assignee: Menon Renewable Resources, Inc.
    Inventors: Suresh M. Menon, Arul Victor Suresh, Samantha S. Orchard, Kashinatham Alisala, Jagadish C. Sircar, Sara Ingegard Hash
  • Methods for Treating HCV
    Publication number: 20140107016
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Application
    Filed: December 23, 2013
    Publication date: April 17, 2014
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
  • Methods for Treating HCV
    Publication number: 20140107017
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Application
    Filed: December 23, 2013
    Publication date: April 17, 2014
    Applicant: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
  • Methods for treating HCV
    Patent number: 8685984
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 1, 2014
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
  • Methods for treating HCV
    Patent number: 8680106
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: March 25, 2014
    Assignee: AbbVic Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
  • Methods for treating HCV
    Patent number: 8680048
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 25, 2014
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • METHODS FOR TREATING HCV
    Publication number: 20140057835
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Application
    Filed: July 5, 2013
    Publication date: February 27, 2014
    Applicant: AbbVie Inc.
    Inventors: Barry M. BERNSTEIN, Rajeev M. MENON, Amit KHATRI, Sven MENSING, Sandeep DUTTA, Daniel E. COHEN, Scott C. BRUN, Walid M. AWNI, Emily O. DUMAS, Cheri E. KLEIN, Thomas J. PODSADECKI
  • METHODS FOR TREATING HCV
    Publication number: 20140024579
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Application
    Filed: July 5, 2013
    Publication date: January 23, 2014
    Applicant: AbbVie Inc.
    Inventors: Barry M. BERNSTEIN, Rajeev M. MENON, Amit KHATRI, Sven MENSING, Sandeep DUTTA, Daniel E. COHEN, Scott C. BRUN, Walid M. AWNI, Emily O. DUMAS, Cheri E. KLEIN, Thomas J. PODSADECKI
  • Observing Embedded Signals Of Varying Clock Domains
    Publication number: 20140006836
    Abstract: Observability of internal system-on-chip signals is a difficult problem and it is particularly difficult to observe and debug transactions with different clock domains. However, one embodiment provides observability of internal signals from multiple internal blocks having varying clock domains such as synchronous (common clock) and asynchronous (non common clock) domains. An embodiment provides simultaneous observability of debug data from both synchronous and asynchronous clock domains. An embodiment may also allow sending debug data from both synchronous and asynchronous domains from the SoC. One embodiment outputs internal signals on output pins of the SoC, thereby allowing transactions from one clock domain to be tracked to another clock domain and allowing for the determination of the relationship between the data of differing clock domains. Other embodiments are described herein.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 2, 2014
    Inventors: Sankaran M. Menon, Binta M. Patel, Bo Jiang, Nancy G. Woodbridge
  • NO-TOUCH STRESS TESTING OF MEMORY I/O INTERFACES
    Publication number: 20140006864
    Abstract: Embodiments are generally directed no-touch stress testing of memory input/output (I/O) interfaces. An embodiment of a memory device includes a system element to be coupled with a dynamic random-access memory (DRAM), the system element including a memory interface for connection with the DRAM, the interface including a driver and a receiver, a memory controller for control of the DRAM, and a timing stress testing logic for testing of the I/O interface.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 2, 2014
    Applicant: Intel Corporation
    Inventors: Sankaran M. Menon, Robert R. Roeder
  • METHOD AND APPARATUS FOR TESTING I/O BOUNDARY SCAN CHAIN FOR SOC'S HAVING I/O'S POWERED OFF BY DEFAULT
    Publication number: 20130346816
    Abstract: Methods and apparatus for testing Input/Output (I/O) boundary scan chains for Systems on a Chip (SoCs) having I/Os that are powered off by default. Some methods and apparatus include implementation of boundary scan chain bypass routing schemes that selectively route a boundary scan chain path around I/O interfaces and/or ports that are powered off by default. Other techniques include selectively power-on I/Os that are powered off by default in a manner that is independent of SoC facilities for controlling the power state of the I/Os during SoC runtime operations. Various schemes facilitate boundary scan testing in accordance with IEEE Std.-1149.1 methodology.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 26, 2013
    Inventors: Sankaran M. Menon, Robert R. Roeder, Liwei E. Ju
  • APPARATUS, SYSTEM AND METHOD FOR A COMMON UNIFIED DEBUG ARCHITECTURE FOR INTEGRATED CIRCUITS AND SoCs
    Publication number: 20130339790
    Abstract: A system and method for a common unified debug architecture for integrated circuits and System on Chips (SoCs) are provided. A system consistent with the present disclosure may comprise of an integrated circuit or SoC which includes a display port, plurality of logic blocks, and debug logic. The debug logic may receive debug data from one or more of the plurality of logic blocks in response to the integrated circuit or SoC operating in a debug mode. In addition, control logic coupled to the debug logic. The control logic provides display data to the display port in response to the integrated circuit operating in an operational mode. The control logic further directs high-speed debug data to the display port in response to the integrated circuit or SoC operating in the debug mode. The high-speed debug data is to be based on the debug data.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Inventors: Sankaran M. Menon, Rajendra S. Yavatkar, Eyal Dolev, Sridhar Valluru, Ramana Rachakonda
  • METHOD AND APPARATUS FOR OUTPUT OF HIGH-BANDWIDTH DEBUG DATA/TRACES IN ICS AND SOCS USING EMBEDDED HIGH SPEED DEBUG
    Publication number: 20130339789
    Abstract: Methods and apparatus for output of high-bandwidth debug data/traces in electronic devices using embedded high-speed debug port(s). Debug data is received from multiple blocks and buffered in a buffer. The buffer's output is operatively coupled to one or more high-speed serial I/O interfaces via muxing logic during debug test operations. The buffered data is encoded as serialized data and sent over the one or more high-speed serial I/O interfaces to a logic device that receives serialized data and de-serializes it to generate parallel debug data that is provided to a debugger. The buffer may be configured as a bandwidth-adapting buffer that facilitates transfer of debug data that is received at a variable combined data rate outbound via the one or more high-speed serial I/O interfaces at a data rate corresponding to the bandwidth of the serial I/O interfaces.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 19, 2013
    Inventors: Sankaran M. Menon, Sridhar K. Valluru, Ramana Rachakonda
  • Flexible microcavities through spin coating
    Patent number: 8610103
    Abstract: A mechanically flexible array of optically pumped vertical cavity surface emitting lasers, fabricated using spin coating. The array uses InGaP colloidal quantum dots as an active medium and alternating polymer layers of different refractive indices as Bragg mirrors. Enhanced spontaneous emission is produced. The flexible array can be peeled off a substrate, producing a flexible structure that can conform to a wide variety of shapes, and having an emission spectrum that can be mechanically tuned. The flexible array can be used to create a flexible infrared light bandage.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 17, 2013
    Assignee: Research Foundation of the City University of New York
    Inventors: Vinod M. Menon, Nikesh V. Valappil
  • METHOD AND APPARATUS FOR RECOMMENDING PRODUCT FEATURES IN A SOFTWARE APPLICATION IN REAL TIME
    Publication number: 20130290944
    Abstract: A computer implemented method and apparatus for recommending product features in a software application in real time comprising analyzing an object to detect at least one issue to be addressed in the object; identifying at least one user action taken to address the at least one issue in the object; accessing a recommendations library to find at least one recommendation to address the at least one issue in the object; and displaying the at least one recommendation.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 31, 2013
    Applicant: ADOBE SYSTEMS INC.
    Inventors: Anand M. Menon, Gaurav Singh, Anuj Mittal
  • Methods for treating HCV
    Patent number: 8492386
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: July 23, 2013
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Methods for treating HCV
    Patent number: 8466159
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 18, 2013
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein